Vitamin foot and cancer nutrition
Across the supplied background research, quantitative signals are strongest for NYHA stage and in-hospital mortality in German left-ventricular-heart-failure admissions; the skin and nutrition briefings describe a small prior trial signal and baseline nutritional burden, respectively, without completed causal outcome evidence.
Evidence
This day contains three supplied background-research briefings, not independent current-news confirmation. The largest study was a retrospective nationwide German inpatient cohort of 2,616,462 admissions for left ventricular heart failure from 2014–2022. Multivariable logistic regression identified NYHA stage as the strongest reported predictor of in-hospital mortality: odds ratios were 1.596 for NYHA II, 5.290 for NYHA III, and 22.533 for NYHA IV (all p < 0.001). Overall mortality was 8.34% among women (108,461 deaths) and 7.90% among men (103,883 deaths).
The FOOT-C briefing is a planned multi-site, double-blind, randomized placebo-controlled trial in 80 adults with diabetes-related foot ulcers. It will compare 1 g/day oral vitamin C with placebo for eight weeks, measuring ulcer size at baseline and weeks 2, 4, 6, and 8. Its protocol cites a prior randomized trial of 16 participants, where median percentage ulcer healing at eight weeks was 100% with vitamin C versus −14% with placebo.
In preliminary baseline data from the ongoing NCOM prospective multicenter cohort in 11 Chinese hospitals, 604 patients with common malignancies were enrolled. Within 48 hours of admission, 58.61% had moderate or severe malnutrition by mPG-SGA and 23.34% were at nutritional risk by NRS-2002.
Analysis
The heart-failure result is the clearest quantitative association, but it is observational and limited to in-hospital outcomes. The sex pattern differs between overall and most stratified comparisons, so the supplied material does not establish an explanation. FOOT-C tests whether a small prior wound-healing signal persists under a larger, more controlled design; no FOOT-C efficacy or safety findings are available. NCOM quantifies baseline nutritional burden, not effects of nutritional support, treatment tolerance, or survival.
Limitations
The heart-failure data cannot distinguish HFpEF from HFrEF and lack supplied confidence intervals. FOOT-C is a protocol, and the cited prior trial was small. NCOM remains ongoing; longitudinal associations and outcome estimates have not been reported. None of these briefing facts establish broad causal or treatment-benefit conclusions.